Belén Garijo: Merck Group intends to acquire French-based company UnitySC for €155 million
shared a post on LinkedIn: .
“Today, we are excited to announce Merck Group intends to acquire French-based company UnitySC for €155 million. This acquisition aligns with our Electronics business strategy, expands our capabilities and strengthens our portfolio for the semiconductor industry. Specifically, it enhances our ability to benefit from the growth opportunities of Artificial Intelligence as an integrated solutions provider for our customers to develop next-generation chips.
We look forward to leveraging the combined strengths of both organizations to accelerate our innovation pipeline and deliver even greater value to our customers.
Great work done by the team in making this happen. Congratulations to Kai Beckmann and team!”
Belén Garijo is the Chair of the Executive Board and CEO of Merck KGaA, Darmstadt, Germany. She joined the company in 2011 as Chief Operating Officer of the Biopharma business, becoming President and CEO of Healthcare in 2015. In July 2020, Belén Garijo was appointed Vice Chairman of the Executive Board and Deputy CEO in addition to her role as CEO of the Healthcare business.
She moved from Deputy CEO to CEO in May 2021. Under her leadership, Healthcare at Merck KGaA, Darmstadt, Germany, has become a key player in the area of oncology, immunology and immuno-oncology, after the profound repositioning of the portfolio, the reorganization of R&D and the transformation of the commercial model.
Before joining Merck, Belén Garijo served as the Senior Vice President of Global Operations Europe at Sanofi-Aventis and Global Integration Leader of Genzyme after its acquisition by Sanofi. She previously held several local and global executive positions, both in R&D and commercial, at various companies at the forefront of the Healthcare sector. She started her career as a practicing physician at La Paz hospital in Madrid before moving to the pharmaceutical industry. She is a medical doctor, specialized in clinical pharmacology.